Pampaloni, I. et al. The global assessment of OCD. Compr. Psychiatry 118, 152342 (2022).
Karno, M., Golding, J. M., Sorenson, S. B. & Burnam, M. A. The epidemiology of obsessive-compulsive disorder in five us communities. Arch. Gen. Psychiatry 45, 1094–1099 (1988).
Belloch, A., Carrió, C., Cabedo, E. & García-Soriano, G. Discovering what is hidden: the role of non-ritualized covert neutralizing strategies in obsessive-compulsive disorder. J. Behav. Ther. Exp. Psychiatry 49, 180–187 (2015).
Gualtieri, G., Cuomo, A., Pardossi, S. & Fagiolini, A. When standard is not enough: a narrative review of supratherapeutic SSRI doses in resistant obsessive compulsive disorder. J. Clin. Med. 14, e3858 (2025).
Hoexter, M. Q. et al. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology 37, 734–745 (2012).
Johansen, A. et al. Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial. Mol. Psychiatry 28, 4272–4279 (2023).
Coelho, D. R. A. et al. Glutamatergic medications for obsessive-compulsive and related disorders: a systematic review and meta-analysis. JAMA Netw. Open 8, e2452963 (2025).
Conti, D. et al. The use of antipsychotics in obsessive compulsive disorder. Hum. Psychopharmacol. 39, e2893 (2024).
Kammen, A. et al. Neuromodulation of OCD: a review of invasive and non-invasive methods. Front. Neurol. 13, 909264 (2022).
Thamby, A. & Jaisoorya, T. S. Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. Indian J. Psychiatry 61, S51–S57 (2019).
Moreno, F. A., Wiegand, C. B., Taitano, E. K. & Delgado, P. L. Safety, tolerability and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J. Clin. Psychiatry 67, 1735–1740 (2006).
Buot, A. et al. Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey. Sci. Rep. 13, 13378 (2023).
Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).
Muller, F. et al. Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: a randomized trial. Med. 6, 100725 (2025).
Vollenweider, F. X. & Preller, K. H. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat. Rev. Neurosci. 21, 611–624 (2020).
Collins, H. M. Psychedelics for the treatment of obsessive-compulsive disorder: efficacy and proposed mechanisms. Int. J. Neuropsychopharmacol. 27, pyae057 (2024).
Leuzzi, R., Tardivo, G., Pellegrini, L., Albert, U. & Fineberg, N. A. Psychedelics, OCD and related disorders: setting methodological strategies for future studies. J. Obsessive Compuls. Relat. Disord. 45, 100951 (2025).
Owe-Larsson, M., Kaminska, K., Buchalska, B., Mirowska-Guzel, D. & Cudnoch-Jedrzejewska, A. Psilocybin in pharmacotherapy of obsessive-compulsive disorder. Pharmacol. Rep. 76, 911–925 (2024).
Shephard, E. et al. Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder. Mol. Psychiatry 26, 4583–4604 (2021).
Smallwood, J. et al. The default mode network in cognition: a topographical perspective. Nat. Rev. Neurosci. 22, 503–513 (2021).
Bijanki, K. R. et al. Defining functional brain networks underlying obsessive-compulsive disorder (OCD) using treatment-induced neuroimaging changes: a systematic review of the literature. J. Neurol. Neurosurg. Psychiatry 92, 776–786 (2021).
Maia, T. V., Cooney, R. E. & Peterson, B. S. The neural bases of obsessive-compulsive disorder in children and adults. Dev. Psychopathol. 20, 1251–1283 (2008).
Rădulescu, A., Herron, J., Kennedy, C. & Scimemi, A. Global and local excitation and inhibition shape the dynamics of the cortico-striatal-thalamo-cortical pathway. Sci. Rep. 7, 7608 (2017).
Jalal, B., Chamberlain, S. R. & Sahakian, B. J. Obsessive-compulsive disorder: etiology, neuropathology and cognitive dysfunction. Brain Behav. 13, e3000 (2023).
van de Veerdonk, M. M. G. H. et al. The role of the dorsal anterior cingulate cortex in obsessive-compulsive disorder. Deep Brain Stimul. 3, 1–7 (2023).
Grutzmann, R. et al. Error-related brain activity in patients with obsessive-compulsive disorder and unaffected first-degree relatives: evidence for protective patterns. Biol. Psychiatry Glob. Open Sci. 2, 79–87 (2022).
van der Straten, A. L., Denys, D. & van Wingen, G. A. Impact of treatment on resting cerebral blood flow and metabolism in obsessive compulsive disorder: a meta-analysis. Sci. Rep. 7, 17464 (2017).
Goncalves, O. F. et al. Patterns of default mode network deactivation in obsessive compulsive disorder. Sci. Rep. 7, 44468 (2017).
Chen, Y. et al. Altered network homogeneity of the default-mode network in drug-naive obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 93, 77–83 (2019).
Azarias, F. R., Almeida, G. H. D. R., de Melo, L. F., Rici, R. E. G. & Maria, D. A. The journey of the default mode network: development, function and impact on mental health. Biology 14, 395 (2025).
Perera, M. P. N., Gotsis, E. S., Bailey, N. W., Fitzgibbon, B. M. & Fitzgerald, P. B. Exploring functional connectivity in large-scale brain networks in obsessive-compulsive disorder: a systematic review of EEG and fMRI studies. Cereb. Cortex 34, bhae327 (2024).
Menon, V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn. Sci. 15, 483–506 (2011).
Posner, J. et al. Increased functional connectivity between the default mode and salience networks in unmedicated adults with obsessive-compulsive disorder. Hum. Brain Mapp. 38, 678–687 (2017).
Li, H. et al. Dysregulated connectivity configuration of triple-network model in obsessive-compulsive disorder. Mol. Psychiatry 30, 3138–3149 (2025).
Stern, E. R., Fitzgerald, K. D., Welsh, R. C., Abelson, J. L. & Taylor, S. F. Resting-state functional connectivity between fronto-parietal and default mode networks in obsessive-compulsive disorder. PLoS ONE 7, e36356 (2012).
Koch, K. et al. Increased default mode network connectivity in obsessive-compulsive disorder during reward processing. Front. Psychiatry 9, 254 (2018).
Misir, E., Alici, Y. H. & Kocak, O. M. Functional connectivity in rumination: a systematic review of magnetic resonance imaging studies. J. Clin. Exp. Neuropsychol. 45, 928–955 (2023).
Chen, Y. H. et al. Decreased intrinsic functional connectivity of the salience network in drug-naive patients with obsessive-compulsive disorder. Front. Neurosci. 12, 889 (2018).
Geffen, T. et al. Functional connectivity alterations between default mode network and occipital cortex in patients with obsessive-compulsive disorder (OCD). Neuroimage Clin. 33, 102915 (2022).
Gursel, D. A. et al. Frontoparietal and salience network alterations in obsessive-compulsive disorder: insights from independent component and sliding time window analyses. J. Psychiatry Neurosci. 45, 214–221 (2020).
Lopez-Gimenez, J. F. & Gonzalez-Maeso, J. Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways. Curr. Top. Behav. Neurosci. 36, 45–73 (2018).
Szpręgiel, I. & Bysiek, A. Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases. Pharmacol. Rep. 76, 1297–1304 (2024).
Petruskova, A. et al. Serotonergic psychedelics rapidly modulate evoked glutamate release in cultured cortical neurons. J. Neurochem. 169, e70020 (2025).
Roseman, L. et al. Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory. J. Psychopharmacol. 33, 1076–1087 (2019).
Peill, J. M. et al. Validation of the psychological insight scale: a new scale to assess psychological insight following a psychedelic experience. J. Psychopharmacol. 36, 31–45 (2022).
Ostrand, A. et al. Defining, ‘psychedelic’. Preprint at PsyArXiv https://doi.org/10.31234/osf.io/5ybhk_v1 (2025).
Pastre, M. et al. Serotonergic underpinnings of obsessive-compulsive disorder: a systematic review and meta-analysis of neuroimaging findings. Psychiatry Clin. Neurosci. 79, 48–59 (2025).
Wacker, D. et al. Crystal structure of an LSD-bound human serotonin receptor. Cell 168, 377–389 e312 (2017).
Holze, F. et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 47, 1180–1187 (2022).
Robison, R. et al. Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA 334, 1358–1372 (2025).
De Gregorio, D., Comai, S., Posa, L. & Gobbi, G. D-lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int. J. Mol. Sci. 17, 1953 (2016).
Dong, M. X., Chen, G. H. & Hu, L. Dopaminergic system alteration in anxiety and compulsive disorders: a systematic review of neuroimaging studies. Front. Neurosci. 14, 608520 (2020).
Caravaggio, F. et al. Lower striatal dopamine D2/3 receptor availability in obsessive-compulsive disorder: a meta-analysis of [11C]-raclopride and [123I]-IBZM studies. J. Obsessive Compuls. Relat. Disord. 28, 100618 (2021).
Ducasse, D. et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology(Berl.) 231, 3765–3770 (2014).
Gallo, E. F. Disentangling the diverse roles of dopamine D2 receptors in striatal function and behavior. Neurochem. Int. 125, 35–46 (2019).
Gattuso, J. J. et al. Default mode network modulation by psychedelics: a systematic review. Int. J. Neuropsychopharmacol. 26, 155–188 (2023).
Sakashita, Y. et al. Effect of psilocin on extracellular dopamine and serotonin levels in the mesoaccumbens and mesocortical pathway in awake rats. Biol. Pharm. Bull. 38, 134–138 (2015).
Burguiere, E., Monteiro, P., Mallet, L., Feng, G. & Graybiel, A. M. Striatal circuits, habits and implications for obsessive-compulsive disorder. Curr. Opin. Neurobiol. 30, 59–65 (2015).
Biria, M. et al. Cortical glutamate and GABA are related to compulsive behaviour in individuals with obsessive compulsive disorder and healthy controls. Nat. Commun. 14, 3324 (2023).
Taddeucci, A. et al. Presynaptic 5-HT2A-mGlu2/3 receptor-receptor crosstalk in the prefrontal cortex: metamodulation of glutamate exocytosis. Cells 11, 3035 (2022).
Mason, N. L. et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology 45, 2003–2011 (2020).
Wu, K., Hanna, G. L., Rosenberg, D. R. & Arnold, P. D. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol. Biochem. Behav. 100, 726–735 (2012).
Reiff, C. M. et al. Psychedelics and psychedelic-assisted psychotherapy. Am. J. Psychiatry 177, 391–410 (2020).
Carhart-Harris, R. L. et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc. Natl Acad. Sci. USA 113, 4853–4858 (2016).
Muller, F., Dolder, P. C., Schmidt, A., Liechti, M. E. & Borgwardt, S. Altered network hub connectivity after acute LSD administration. Neuroimage Clin. 18, 694–701 (2018).
Carhart-Harris, R. The entropic brain today. Preprint at PsyArXiv https://doi.org/10.31234/osf.io/ubzq3_v1 (2025).
Siegel, J. S. et al. Psilocybin desynchronizes the human brain. Nature 632, 131–138 (2024).
Daws, R. E. et al. Increased global integration in the brain after psilocybin therapy for depression. Nat. Med. 28, 844–851 (2022).
Carhart-Harris, R. L. et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci. Rep. 7, 13187 (2017).
Jiang, Q. et al. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell 189, 659–675 (2026).
Deco, G. et al. Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression. Nat. Ment. Health 2, 1096–1110 (2024).
Pasquini, L., Palhano-Fontes, F. & Araujo, D. B. Subacute effects of the psychedelic ayahuasca on the salience and default mode networks. J. Psychopharmacol. 34, 623–635 (2020).
Cheng, S. et al. The comorbidity of anxiety and depression symptoms in obsessive-compulsive disorder: a network analysis. Front. Psychiatry 16, 1567448 (2025).
Preller, K. H. et al. Effective connectivity changes in LSD-induced altered states of consciousness in humans. Proc. Natl Acad. Sci. USA 116, 2743–2748 (2019).
Avram, M. et al. Bridging the gap? Altered thalamocortical connectivity in psychotic and psychedelic states. Front. Psychiatry 12, 706017 (2021).
Carhart-Harris, R. L. et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc. Natl Acad. Sci. USA 109, 2138–2143 (2012).
Park, J., Kim, T., Kim, M., Lee, T. Y. & Kwon, J. S. Functional connectivity of the striatum as a neural correlate of symptom severity in patient with obsessive-compulsive disorder. Psychiatry Investig. 17, 87–95 (2020).
Prasad, A. A. & Wallen-Mackenzie, A. Architecture of the subthalamic nucleus. Commun. Biol. 7, 78 (2024).
Welter, M. L. et al. Basal ganglia dysfunction in OCD: subthalamic neuronal activity correlates with symptoms severity and predicts high-frequency stimulation efficacy. Transl. Psychiatry 1, e5 (2011).
Rappel, P. et al. Subthalamic theta activity: a novel human subcortical biomarker for obsessive compulsive disorder. Transl. Psychiatry 8, 118 (2018).
Buot, A. et al. Emotions modulate subthalamic nucleus activity: new evidence in obsessive-compulsive disorder and Parkinson’s disease patients. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 6, 556–567 (2021).
Brownstien, M. et al. Striking long-term beneficial effects of single dose psilocybin and psychedelic mushroom extract in the SAPAP3 rodent model of OCD-like excessive self-grooming. Mol. Psychiatry 30, 1172–1183 (2025).
Delli Pizzi, S. et al. LSD-induced changes in the functional connectivity of distinct thalamic nuclei. Neuroimage 283, 120414 (2023).
Gaddis, A. et al. Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity. Neuroimage 260, 119434 (2022).
Carhart-Harris, R. L. et al. Canalization and plasticity in psychopathology. Neuropharmacology 226, 109398 (2023).
Zeifman, R. J. et al. From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS). Sci. Rep. 15, 3651 (2025).
Carhart-Harris, R. L. et al. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. Br. J. Psychiatry 200, 238–244 (2012).
Karadag, F. et al. The comparison of pre- and post-treatment 99mTc HMPAO brain SPECT images in patients with obsessive-compulsive disorder. Psychiatry Res. 213, 169–177 (2013).
Zambrano-Vazquez, L. & Allen, J. J. Differential contributions of worry, anxiety, and obsessive compulsive symptoms to ERN amplitudes in response monitoring and reinforcement learning tasks. Neuropsychologia 61, 197–209 (2014).
Saxena, S. et al. Rapid effects of brief intensive cognitive-behavioral therapy on brain glucose metabolism in obsessive-compulsive disorder. Mol. Psychiatry 14, 197–205 (2009).
Bracco, L., Dusi, N., Moltrasio, C., Brambilla, P. & Delvecchio, G. Structural and functional brain imaging after treatment with selective-serotonin reuptake-inhibitors in obsessive-compulsive disorder: a mini review. J. Affect. Disord. 345, 141–148 (2024).
Kim, M., Jung, W. H., Shim, G. & Kwon, J. S. The effects of selective serotonin reuptake inhibitors on brain functional networks during goal-directed planning in obsessive-compulsive disorder. Sci. Rep. 10, 20619 (2020).
Carhart-Harris, R. & Nutt, D. Serotonin and brain function: a tale of two receptors. J. Psychopharmacol. 31, 1091–1120 (2017).
Aleksandrova, L. R. & Phillips, A. G. Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics. Trends Pharmacol. Sci. 42, 929–942 (2021).
Weiss, F. et al. Psychedelic-induced neural plasticity: a comprehensive review and a discussion of clinical implications. Brain Sci. 15, 117 (2025).
Moliner, R. et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat. Neurosci. 26, 1032–1041 (2023).
Ly, C. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170–3182 (2018).
Christoffel, D. J., Golden, S. A. & Russo, S. J. Structural and synaptic plasticity in stress-related disorders. Rev. Neurosci. 22, 535–549 (2011).
Duman, R. S. & Aghajanian, G. K. Synaptic dysfunction in depression: potential therapeutic targets. Science 338, 68–72 (2012).
Vargas, M. V. et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379, 700–706 (2023).
Shao, L. X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535–2544 e2534 (2021).
Hutten, N. et al. Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers. ACS Pharmacol. Transl. Sci. 4, 461–466 (2021).
Butkovich, L. M. et al. Action inflexibility and compulsive-like behavior accompany neurobiological alterations in the anterior orbitofrontal cortex and associated striatal nuclei. Sci. Rep. 15, 1863 (2025).
Zhang, X. et al. Pathological networking of gray matter dendritic density with classic brain morphometries in OCD. JAMA Netw. Open 6, e2343208 (2023).
Oliveira-Maia, A. J. & Castro-Rodrigues, P. Brain-derived neurotrophic factor: a biomarker for obsessive-compulsive disorder? Neurosci. 9, 134 (2015).
Brandrup, E. & Vanggaard, T. LSD treatment in a severe case of compulsive neurosis. Acta Psychiatr. Scand. 55, 127–141 (1977).
Leonard, H. L. & Rapoport, J. L. Relief of obsessive-compulsive symptoms by LSD and psilocin. Am. J. Psychiatry 144, 1239–1240 (1987).
Wilcox, J. A. Psilocybin and obsessive compulsive disorder. J. Psychoactive Drugs 46, 393–395 (2014).
Lugo-Radillo, A. & Cortes-Lopez, J. M. Long-term amelioration of OCD symptoms in a patient with chronic consumption of psilocybin-containing mushrooms. J. Psychoactive Drugs 53, 146–148 (2021).
Kelmendi, B. et al. Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: a case report. Heliyon 8, e12135 (2022).
Pellegrini, L. et al. Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: a pharmacological challenge study. Compr. Psychiatry 142, 152619 (2025).
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M. & Olson, D. E. Psychedelics and other psychoplastogens for treating mental illness. Front. Psychiatry 12, 727117 (2021).
Lewis, V. et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 42, 112203 (2023).
Carhart-Harris, R. L. & Friston, K. J. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol. Rev. 71, 316–344 (2019).
Maloney, G., Ching, T., Kichuk, S. A., Pittenger, C. & Kelmendi, B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Res. 336, 115907 (2024).
Doss, M. K. et al. Models of psychedelic drug action: modulation of cortical-subcortical circuits. Brain 145, 441–456 (2022).
Deppermann, S., Storchak, H., Fallgatter, A. J. & Ehlis, A. C. Stress-induced neuroplasticity: (mal)adaptation to adverse life events in patients with PTSD—a critical overview. Neuroscience 283, 166–177 (2014).
Carhart-Harris, R. L. et al. Psychedelics and the essential importance of context. J. Psychopharmacol. 32, 725–731 (2018).
Aday, J. S., Davis, A. K., Mitzkovitz, C. M., Bloesch, E. K. & Davoli, C. C. Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects. ACS Pharmacol. Transl. Sci. 4, 424–435 (2021).
Sabe, M. et al. Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies. Mol. Psychiatry 30, 1223–1255 (2025).
Myran, D. T. et al. Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder. JAMA Psychiatry 82, 142–150 (2025).
Alessandro, D. L. et al. Obsessive-compulsive symptoms in individuals at clinical high risk for psychosis: a 2-year longitudinal study. Schizophr. Res. 274, 11–20 (2024).